natgillin/translations-raw huggingface dataset:
I et interaktionsstudie med frivillige raske personer, samtidig administration af deferasirox (30/mg/kg/dag, 4 dage), en moderat inhibitor af CYP2C8 og CYP3A4, og repaglinid (enkelt dosis, 0,5 mg) resulterede i en 2,3 gange øgning (90% CI [2,03-2,63]) af systemisk eksponeret (AUC) repaglinid i forhold til kontrol, en 1,6 gange (90% CI [1,42-1,84]) øgning af Cmax, og et mindre, signifikant fald af blodglucoseværdier. 
In an interaction study with healthy volunteers, co-administration of deferasirox (30 mg/kg/day, 4 days), a moderate inhibitor of CYP2C8 and CYP3A4, and repaglinide (single dose, 0.5 mg) resulted in an increase in repaglinide systemic exposure (AUC) to 2.3-fold (90% CI [2.03-2.63]) of control, a 1.6-fold (90% CI [1.42-1.84]) increase in Cmax, and a small, significant decrease in blood glucose values.
Når patienter, der indtager repaglinid, starter eller ophører med at tage disse stoffer, skal de overvåges grundigt for ændring i blodglucoseregulering. 
When these medications are administered to or withdrawn from a patient receiving repaglinide, the patient should be observed closely for changes in glycaemic control.
Der er ikke udført studier hos ammende kvinder. 
There are no studies in breast-feeding women.
Da interaktionen ikke er påvist ved doser af repaglinid, som er højere end 0,25 mg, skal samtidig brug af ciclosporin med repaglinid undgås. 
Since the interaction has not been established with dosages higher than 0.25 mg for repaglinide, the concomitant use of ciclosporin with repaglinide should be avoided.
Farmako-terapeutisk gruppe: Lægemidler anvendt mod diabetes, andre blodglucose sænkende lægemidler, ekskl. 
Pharmaco-therapeutic group: Drugs used in diabetes, other blood glucose lowering drugs, excl. insulins, ATC code: A10BX02
Samtidig administration af 200 mg ketoconazole øger repaglinidoptagelsen (AUC og Cmax) med 1,2 gange med ændring på mindre end 8% af blodglucoseprofilerne (en enkelt dosis på 4 mg repaglinid). 
Co-administration of 200 mg ketoconazole increased the repaglinide (AUC and Cmax) by 1.2-fold with profiles of blood glucose concentrations altered by less than 8% when administered concomitantly (a single dose of 4 mg repaglinide).
Anvendelse af repaglinid kan være forbundet med en forhøjet incidens af akut koronarsyndrom (f.eks. myokardieinfarkt) se pkt. 
The use of repaglinide might be associated with an increased incidence of acute coronary syndrome (e.g. myocardial infarction), see sections 4.8 and 5.1.
I et interaktionsstudie med frivillige raske personer, øgede samtidig administration af clopidogrel (300 mg opstartsdosis), en CYP2C8 inhibitor, eksponering af repaglinid (AUC0-∞) 5,1 gange, og ved kontinuerlig administration (75 mg daglig dosis) eksponering af repaglinid (AUC0-∞) 3,9 gange. 
In an interaction study with healthy volunteers, co-administration of clopidogrel (300 mg loading dose), a CYP2C8 inhibitor, increased repaglinide exposure (AUC0-∞) 5.1-fold and continued administration (75 mg daily dose) increased repaglinide exposure (AUC0-∞) 3.9-fold.
• Hvis du har problemer med dine nyrer. 
• if you have kidney problems.
Enyglid 1 mg tabletter 
Enyglid 1 mg tablets
Repaglinid kan, som andre β-cellestimulerende orale antidiabetika, forårsage hypoglykæmi. 
Repaglinide, like other insulin secretagogues, is capable of producing hypoglycaemia.
I et studie udført på frivillige raske personer, øgede samtidig administration af repaglinid (en enkelt dosis på 0,25 mg) og ciclosporin (gentagen dosis på 100 mg) AUC og Cmax for repaglinid omkring 2,5 gange og 1,8 gange respektivt. 
In a study conducted in healthy volunteers, the concomitant administration of repaglinide (a single dose of 0.25 mg) and ciclosporin (repeated dose at 100 mg) increased repaglinide AUC and Cmax about 2.5-fold and 1.8-fold respectively.
Enyglid 2 mg tabletter 
Enyglid 2 mg tablets
Enyglid 0,5 mg tabletter 
Enyglid 0.5 mg tablets
Meget sjældne bivirkninger (kan forekomme hos færre end 1 ud af 10.000 personer) 
Very rare (may affect up to 1 in 10,000 people):
Er du i tvivl så spørg lægen eller på apoteket. 
• If you have any further questions, ask your doctor or pharmacist.
I et interaktionsstudie med raske frivillige vistes, at samtidig administration af 250 mg clarithromycin, en potent mekanismebaseret CYP3A4-hæmmer, øgede repaglinidoptagelsen (AUC) 1,4 gange og Cmax 1,7 gange samt øgede den gennemsnitlige tilvækst i repaglinidoptagelsen AUC af serum insulin 1,5 gange og maksimumkoncentrationen 1,6 gange. 
In an interaction study in healthy volunteers, co-administration of 250 mg clarithromycin, a potent mechanism-based inhibitor of CYP3A4, slightly increased the repaglinide (AUC) by 1.4-fold and Cmax by 1.7-fold and increased the mean incremental AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold.
• Ofte har hypoglykæmi 
• have frequent hypos,
Hver tablet indeholder 0,5 mg repaglinid. 
Each tablet contains 0.5 mg repaglinide.
Repaglinid, sænker øjeblikkeligt blodglucoseniveauerne ved at stimulere sekretionen af insulin fra pankreas. 
Repaglinide lowers the blood glucose levels acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning β-cells in the pancreatic islets.
• Betablokkere (mod forhøjet blodtryk eller hjertelidelser) 
• Beta blockers (used to treat high blood pressure orheart conditions).
Repaglinid er et oralt β-celle stimulerende korttidsvirkende antidiabeticum. 
Repaglinide is a short-acting oral secretagogue.
Samtidig administration af trimetoprim (160 mg 2 gange dagligt), en moderat CYP2C8-hæmmer, og repaglinid (en enkelt dosis på 0,25 mg) øger repaglinid AUC, Cmax og t½ (henholdsvis 1,6, 1,4 og 1,2 gange) uden statistisk signifikans på blodglucoseniveauerne. 
Co-administration of trimethoprim (160 mg twice daily), a moderate CYP2C8 inhibitor, and repaglinide (a single dose of 0.25 mg) increased the repaglinide AUC, Cmax and t½ (1.6-fold, 1.4-fold and 1.2-fold respectively) with no statistically significant effects on the blood glucose levels.
Enyglid 0,5 mg tabletter Hver tablet indeholder 0,5 mg repaglinid. 
Enyglid 0.5 mg tablets Each tablet contains 0.5 mg repaglinide.
Hvis kombinationen synes nødvendig, skal der foretages omhyggelig klinisk overvågning og monitorering af blodglucosen (se pkt. 
If the combination appears necessary, careful clinical and blood glucose monitoring should be performed (see section 4.4).
Repaglinid bør kun ordineres, hvis der efter behandling med diæt, motion og vægttab stadig er ringe blodglucosekontrol og symptomer på diabetes mellitus. 
Repaglinide should only be prescribed if poor blood glucose control and symptoms of diabetes persist despite adequate attempts at dieting, exercise and weight reduction.
Derfor bør lægen overveje mulige interaktioner: 
A number of medicinal products are known to influence repaglinide metabolism, possible interactions should therefore be taken into account by the physician:
Enyglid 1 mg tabletter Hver tablet indeholder 1 mg repaglinid. 
Enyglid 1 mg tablets Each tablet contains 1 mg repaglinide.
croscarmellosenatrium, povidon K25, glycerol, magnesiumstearat, meglumin, poloxamerer, gul jernoxid (E172) kun i tabletter à 1 mg og rød jernoxid (E172) kun i tabletter à 2 mg. 
• The other ingredients are: microcrystalline cellulose (E460); calcium hydrogen phosphate, anhydrous; croscarmellose sodium; povidone K25; glycerol; magnesium stearate; meglumine; poloxamer; yellow iron oxide (E172) only in the 1 mg tablets and red iron oxide (E172) only in the 2 mg tablets
Hver tablet indeholder 1 mg repaglinid. 
Each tablet contains 1 mg repaglinide.
Enyglid 2 mg tabletter Hver tablet indeholder 2 mg repaglinid. 
Enyglid 2 mg tablets Each tablet contains 2 mg repaglinide.
• Monoaminooxidasehæmmere eller (MAO-hæmmere) (mod depression) 
• Monoamine oxidase inhibitors (MAOI) (used to treat depression).
• ACE-hæmmere (mod hjertelidelser) 
• ACE-inhibitors (used to treat heart conditions).
Sådan skal du tage Enyglid 
How to take Enyglid
Hver tablet indeholder 2 mg repaglinid. 
Each tablet contains 2 mg repaglinide.
Almindelige bivirkninger (kan forekomme hos mellem 1 og 10 ud af 100 personer) 
Common (may affect up to 1 in 10 people):
Opbevaring 
Maintenance
Samtidig administration af gemfibrozil (600 mg 2 gange dagligt), en CYP2C8-hæmmer, og repaglinid (en enkelt dosis på 0,25 mg) øgede repaglinidoptagelsen (AUC) med 8,1 gange og Cmax med 2,4 gange hos frivillige raske personer. 
Co-administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and repaglinide (a single dose of 0.25 mg) increased the repaglinide AUC 8.1-fold and Cmax 2.4-fold in healthy volunteers.
• Gemfibrozil (mod kolesterol i blodet) 
• Gemfibrozil (used to treat high blood fats).
Otte procent af en indgiven dosis af repaglinid udskilles gennem nyrerne. 
Eight percent of one dose of repaglinide is excreted through the kidneys and total plasma clearance of the product is decreased in patients with renal impairment.
Synsforstyrrelser * 
Refraction disorder*
Der er rapporteret isolerede tilfælde af leverenzymstigning under behandling med repaglinid. 
Abnormal hepatic function, increased liver enzymes Isolated cases of increased liver enzymes have been reported during treatment with repaglinide.
Brugen af repaglinid til patienter med sekundært behandlingssvigt overfor andre β-celle stimulerende orale antidiabetika er ikke undersøgt i kliniske studier. 
Use of repaglinide in case of secondary failure to insulin secretagogues has not been investigated in clinical trials.
Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. 
Check with your doctor if you are not sure.
4.4 og 4.5 for at bestemme dosis. 
In the case of concomitant use with other active substances refer to sections 4.4 and 4.5 to assess the dosage.
Hvis det er nødvendigt at give trimetoprim og repaglinid samtidig, skal blodglucosen måles omhyggeligt, og der skal være tæt klinisk observation. 
If concomitant use is necessary, careful monitoring of blood glucose and close clinical monitoring should be performed.
Samtidig anvendelse 
Concomitant use
• Opkastning 
• Vomiting
- Lægen har ordineret Enyglid til dig personligt. 
• This medicine has been prescribed for you only.
Enyglid 1 mg tabletter Tabletterne er svagt brun-gule, runde, bikonvekse med facetterede kanter og eventuelt mørkere pletter. 
Enyglid 1 mg tablets The tablets are pale brown-yellow, round, biconvex with bevelled edges and possible darker spots.
Hvis det er nødvendigt at bruge dem samtidig, skal blodglucosen måles omhyggeligt, og der skal være tæt klinisk observation (se pkt. 
If concomitant use is necessary, careful monitoring of blood glucose and close clinical monitoring should be performed (see section 4.4).
Enyglid 0,5 mg tabletter Tabletterne er hvide, runde og bikonvekse med facetterede kanter. 
What Enyglid looks like and contents of the pack The 0.5 mg tablets are white, round and biconvex with bevelled edges.
Maksimalt plasmaniveau indtræder en time efter indtagelsen. 
The peak plasma level occurs within one hour post administration.
Tabletterne à 2 mg er lyserøde, marmorerede, runde, bikonvekse med facetterede kanter og muligvis mørkere pletter. 
The 2 mg tablets are pink, marbled, round, biconvex with bevelled edges and possible darker spots.
Repaglinid påvirkes ikke af nedsat nyrefunktion (se pkt. 
not affected by renal disorders (see section 5.2).
Vedligeholdelsesdosis 
Initial dose
Enyglid 1 mg tabletter 30 tabletter: EU/1/09/580/007 60 tabletter: EU/1/09/580/008 90 tabletter: EU/1/09/580/009 120 tabletter: EU/1/09/580/010 180 tabletter: EU/1/09/580/020 270 tabletter: EU/1/09/580/011 360 tabletter: EU/1/09/580/012 
Enyglid 1 mg tablets 30 tablets: EU/1/09/580/007 60 tablets: EU/1/09/580/008 90 tablets: EU/1/09/580/009 120 tablets: EU/1/09/580/010 180 tablets: EU/1/09/580/020 270 tablets: EU/1/09/580/011 360 tablets: EU/1/09/580/012
6.6 Regler for destruktion og anden håndtering 
6.6 Special precautions for disposal
60 tabletter: EU/1/09/580/014 
60 tablets: EU/1/09/580/014
30 tabletter: EU/1/09/580/013 
30 tablets: EU/1/09/580/013
Tabletterne à 1 mg er svagt brun-gule, runde, bikonvekse med facetterede kanter og muligvis mørkere pletter. 
The 1 mg tablets are pale brown-yellow, round, biconvex with bevelled edges and possible darker spots.
90 tabletter: EU/1/09/580/015 
90 tablets: EU/1/09/580/015
30 tabletter: EU/1/09/580/007 
30 tablets: EU/1/09/580/007
Synsforstyrrelser 
Refraction disorders
30 tabletter: EU/1/09/580/001 
30 tablets: EU/1/09/580/001
Det skal du vide, før du begynder at tage Enyglid Sådan skal du tage Enyglid Bivirkninger 
What you need to know before you take Enyglid 3.
120 tabletter: EU/1/09/580/004 180 tabletter: EU/1/09/580/019 270 tabletter: EU/1/09/580/005 360 tabletter: EU/1/09/580/006 
120 tablets: EU/1/09/580/004 180 tablets: EU/1/09/580/019 270 tablets: EU/1/09/580/005 360 tablets: EU/1/09/580/006
Amning 
Meglumine
• Mavesmerter 
• Stomach pain
60 tabletter: EU/1/09/580/002 
60 tablets: EU/1/09/580/002
Initialdosis 
Posology
120 tabletter: EU/1/09/580/010 180 tabletter: EU/1/09/580/020 270 tabletter: EU/1/09/580/011 360 tabletter: EU/1/09/580/012 
120 tablets: EU/1/09/580/010 180 tablets: EU/1/09/580/020 270 tablets: EU/1/09/580/011 360 tablets: EU/1/09/580/012
Enyglid 0,5 mg tabletter 30 tabletter: EU/1/09/580/001 60 tabletter: EU/1/09/580/002 90 tabletter: EU/1/09/580/003 120 tabletter: EU/1/09/580/004 180 tabletter: EU/1/09/580/019 270 tabletter: EU/1/09/580/005 360 tabletter: EU/1/09/580/006 
Enyglid 2 mg tablets 30 tablets: EU/1/09/580/013 60 tablets: EU/1/09/580/014 90 tablets: EU/1/09/580/015 120 tablets: EU/1/09/580/016 180 tablets: EU/1/09/580/021 270 tablets: EU/1/09/580/017 360 tablets: EU/1/09/580/018
120 tabletter: EU/1/09/580/016 180 tabletter: EU/1/09/580/021 270 tabletter: EU/1/09/580/017 360 tabletter: EU/1/09/580/018 
120 tablets: EU/1/09/580/016 180 tablets: EU/1/09/580/021 270 tablets: EU/1/09/580/017 360 tablets: EU/1/09/580/018
60 tabletter: EU/1/09/580/008 
60 tablets: EU/1/09/580/008
90 tabletter: EU/1/09/580/003 
90 tablets: EU/1/09/580/003
90 tabletter: EU/1/09/580/009 
90 tablets: EU/1/09/580/009
Mavesmerter og diarré 
Abdominal pain, diarrhoea Common Vomiting, constipation
Tabletterne à 0,5 mg er hvide, runde og bikonvekse med facetterede kanter. 
The tablets are white, round and biconvex with bevelled edges.
Kombinationsbehandling med andre β-celle stimulerende orale antidiabetika er ikke undersøgt klinisk. 
Trials investigating the combination with other insulin secretagogues have not been performed.
1 Artikel 29, stk. 4 i direktiv 2001/83/EF, som ændret. 
1 Article 29(4) of Directive 2001/83/EC, as amended.
Referencemedlemsstaten var Det Forenede Kongerige, og de berørte medlemsstater var Østrig, Belgien, Tjekkiet, Danmark, Finland, Frankrig, Tyskland, Ungarn, Irland, Nederlandene, Norge, Polen, Portugal, Slovakiet, Spanien og Sverige. 
The Reference Member State was the United Kingdom and the Concerned Member States were Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Hungary, Ireland, the Netherlands, Norway, Poland, Portugal, the Slovak Republic, Spain and Sweden.
Disse medlemsstater kunne ikke nå til enighed om gensidig anerkendelse af den af referencemedlemsstaten udstedte markedsføringstilladelse. 
These Member States were not able to reach an agreement in respect of the Mutual Recognition of the Marketing Authorisation granted by the Reference Member State.
Listen over de pågældende lægemiddelnavne fremgår af bilag I. De faglige konklusioner findes i bilag II. 
The list of the product names concerned is given in Annex I. The scientific conclusions are provided in Annex II.
Tjekkiet, Spanien og Portugal fremsendte begrundelserne for uenigheden til EMEA den 30. november 2006. 
The Czech Republic, Spain and Portugal referred the reasons for disagreement to the EMEA on 30 November 2006.
Lansoprazol og tilknyttede navne 
Lansoprazole and associated names
Proceduren for gensidig anerkendelse blev indledt den 7. juni 2006. 
The Mutual Recognition Procedure started on 07 June 2006.
Voldgiftsproceduren blev indledt den 14. december 2006 med vedtagelsen af en liste med spørgsmål. 
The arbitration procedure started on 14 December 2006 with the adoption of a list of questions.
Internationalt fællesnavn (INN): lansoprazol 
International Non-Proprietary Name (INN): lansoprazole
Den endelige udtalelse blev omdannet til en afgørelse truffet af Europa-Kommissionen den 18. september 
The final opinion was converted into a Decision by the European Commission on 18 September 2007.
London, den 18. september 2007 EMEA/448438/2007 
London, 18 September 2007 EMEA/283378/2007
Indehaveren af markedsføringstilladelsen fremsendte skriftlige redegørelser den 30. marts 2007. 
The Marketing Authorisation Holder provided written explanations on 30 March 2007.
Udvalget vedtog enstemmigt en positiv udtalelse den 21. juni 2007. 
A positive opinion was adopted by consensus on 21 June 2007.
Grundene til uenigheden var, at nogle af medlemsstaterne havde gjort indsigelser i forbindelse med folkesundheden, fordi der var påvist bioækvivalens i fastende tilstand, men at dette ikke var tilfældet under ikke-fastende tilstande. 
The reasons for disagreement were, that some Member States have raised public health objections on the grounds that while bioequivalence was proven in the fasting state, the same was not the case under fed conditions.
Den udpegede rapportør og medrapportør var henholdsvis dr. Frits Lekkerkerker og dr. Ian Hudson. 
The Rapporteur was Dr. Frits Lekkerkerker and Co-Rapporteur was Dr. Ian Hudson.
Lansoprazol 15 & 30 mg gastro-resistente hårde kapsler er generiske præparater, der indeholder lansoprazol som det aktive stof. 
Lansoprazole 15 & 30 mg gastro-resistant capsules, hard are generic preparations containing lansoprazole as the active substance.
TEVA UK Limited indsendte ansøgninger om gensidig anerkendelse af Lansoprazol og tilknyttede navne, 15 og 30 mg, gastro-resistente kapsler, hårde, på baggrund af den markedsføringstilladelse, som blev udstedt af Det Forenede Kongerige den 9. december 2005. 
TEVA UK Limited submitted applications for mutual recognition of Lansoprazole and associated names, 15 and 30 mg, gastro-resistant capsules, hard, on the basis of the marketing authorisation granted by the United Kingdom on 9 December 2005.
Lansoprazol er en protonpumpehæmmer, der hæmmer mavesyresekretion, og som anvendes til behandling af duodenale og godartede gastriske ulcera, gastroøsofageal reflukssygdom og associerede tilstande. 
Lansoprazole is a proton pump inhibitor that inhibits gastric acid secretion and is used for the treatment of duodenal and benign gastric ulcers, gastro-oesophageal reflux disease and associated conditions.
- 21. juni 2007 var CHMP på grundlag af de samlede forelagte oplysninger og de faglige drøftelser i udvalget af den opfattelse, at risk/benefit-forholdet var gunstigt for Lansoprazol og tilknyttede navne, at indvendingerne fra Tjekkiet, Spanien og Portugal ikke burde forhindre udstedelse af markedsføringstilladelse, og at det/den gældende produktresumé, etikettering og indlægsseddel er de endelige versioner, der er udarbejdet under koordineringsgruppens procedure. 
During their 18 - 21 June 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Lansoprazole and associated names, that the objections raised by the Czech Republic, Spain and Portugal should not prevent the granting of a Marketing Authorisation and that the valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure.
UDTALELSE SOM FØLGE AF EN SAG INDBRAGT I HENHOLD TIL ARTIKEL 29, STK. 41 
OPINION FOLLOWING AN ARTICLE 29(4)1 REFERRAL FOR
Hvis De har smerter, rødmen, hævelse eller sår i munden (meget almindelig). 
• If you have pain, redness, swelling or sores in your mouth (very common).
Den samlede responsrate var 14,1 %. 
The overall response rate was 14.1%.
Tørst og øget vandforbrug 
Thirst and increased water consumption
Det anbefales at bruge handsker. 
The use of gloves is recommended.
Respons (n: kvalificeret til respons) 
Response (n: qualified for response)
Fra et mikrobiologisk synspunkt skal produktet anvendes med det samme. 
From a microbiological point of view, the product should be used immediately.
De vil normalt få infusionen én gang hver tredje uge. 
You should usually receive your infusion once every 3 weeks.
Denne kombination skal anvendes med forsigtighed. 
This combination should be used with caution.
Behandlingen bør genoptages i henhold til retningslinjerne i tabel 2. 
Treatment should be resumed according to the guidelines in Table 2.
Det aktive stof er pemetrexed. 
The active substance is pemetrexed.
Yderligere fortynding er nødvendig, som nedenfor. 
Further dilution is required, as below.
* Definition af hyppighed: Meget almindelig - ≥ 10%; Almindelig - > 5% og < 10%. 
*Definition of frequency terms: Very common - ≥ 10%; Common - > 5% and < 10%.
Læs denne indlægsseddel grundigt, inden De begynder at bruge dette lægemiddel, da den indeholder vigtige oplysninger. 
Read all of this leaflet carefully before you start receiving this medicine because it contains important information for you.
Myelosuppression er normalt den dosisbegrænsende toksicitet. 
Myelosuppression is usually the dose-limiting toxicity.
hvis De for nylig er blevet eller snart skal vaccineres mod gul feber. 
- if you have recently received or are about to receive a vaccine against yellow fever.
Yderligere fortynding er nødvendig. 
Further dilution is required.
Infusionen tager omkring 10 minutter. 
The infusion will last approximately 10 minutes.
Opbevares ved temperaturer under 30 °C 
Store below 30°C
Deres læge vil sammen med Dem drøfte den potentielle risiko ved at tage pemetrexed under graviditet. 
Your doctor will discuss with you the potential risk of taking pemetrexed during pregnancy.
Ikke-småcellet lungecancer 
Non-small cell lung cancer
In vitro-forsøg tyder på, at omtrent 81 % bindes til plasmaproteiner. 
In vitro studies indicate that pemetrexed is approximately 81% bound to plasma proteins.
Vær derfor forsigtig, hvis De kører bil eller betjener maskiner. 
Be careful when driving a car or using machines.
Infusionen af cisplatin tager omkring 2 timer. 
The infusion of cisplatin will last approximately 2 hours.
Overlevelsestid (måneder) 
Survival time (months)
Det andet indholdsstof er mannitol. 
The other ingredient is mannitol.
Der findes mange slags NSAID-præparater med forskellig varighed af det aktive stof. 
There are many sorts of NSAIDs with different durations of activity.
Patienterne fik vedligeholdelsesbehandling indtil sygdomsprogression. 
Patients received maintenance treatment until disease progression.
Deres læge vil bruge dette mål på overfladeareal til at bestemme den rette dosis til Dem. 
Your doctor will use this body surface area to work out the right dose for you.
Anafylaktisk shock (alvorlig allergisk reaktion) 
Anaphylactic shock (severe allergic reaction)
Man skal være særlig opmærksom ved disse patienter, og der bør udvises forsigtighed ved brug af andre radiosensibiliserende stoffer. 
Particular attention should be paid to these patients, and caution exercised with use of other radiosensitising agents.
Det er dog blevet rapporteret, at pemetrexed kan forårsage træthed. 
However, it has been reported that pemetrexed may cause fatigue.
Ud fra den planlagte dato for Deres infusion af pemetrexed og/eller status for Deres nyrefunktion skal Deres læge fortælle Dem, hvilke typer medicin De må tage, og hvornår De må tage dem. 
Based on the planned date of your infusion of pemetrexed and/or on the status of your kidney function, your doctor needs to advise you on which medicines you can take and when you can take them.
Lægen eller hospitalsfarmaceuten beregner den nødvendige dosis ud fra Deres højde og vægt. 
The doctor or hospital pharmacist will work out the dose you need based on your height and weight.
Behandlingen kan eventuelt udsættes, så der er tilstrækkelig tid til rekonvalescens. 
Treatment may be delayed to allow sufficient time for recovery.
Log rank p-værdi* 
Log rank p-value*